Brief: X4 Pharmaceuticals Submits Application To U.S. FDA For Mavorixafor In WHIM Syndrome
05/09/2023 14:00
Sept 5 (Reuters) - X4 Pharmaceuticals Inc XFOR.O :
* X4 PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG
APPLICATION
(NDA) TO U.S. FDA FOR MAVORIXAFOR IN WHIM SYNDROME
* X4 PHARMACEUTICALS- 4WHIM TRIAL MET ITS PRIMARY ENDPOINT
AND KEY
SECONDARY ENDPOINT AND WAS GENERALLY WELL TOLERATED IN TRIAL
Source text for Eikon: ID:nGNX88Gdh6
Further company coverage: XFOR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on X4 Pharmaceuticals
See all newsBrief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
X4 Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: X4 Pharmaceuticals Q2 Operating Expenses USD 25.197 Million
X4 Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule